Logo image of CRON

CRONOS GROUP INC (CRON) Stock Fundamental Analysis

NASDAQ:CRON - Nasdaq - CA22717L1013 - Common Stock - Currency: USD

2.03  -0.02 (-0.98%)

After market: 2.0202 -0.01 (-0.48%)

Fundamental Rating

5

Taking everything into account, CRON scores 5 out of 10 in our fundamental rating. CRON was compared to 198 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CRON was profitable.
In the past year CRON had a positive cash flow from operations.
CRON had negative earnings in 4 of the past 5 years.
CRON had negative operating cash flow in 4 of the past 5 years.
CRON Yearly Net Income VS EBIT VS OCF VS FCFCRON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

1.2 Ratios

With an excellent Return On Assets value of 4.29%, CRON belongs to the best of the industry, outperforming 87.37% of the companies in the same industry.
The Return On Equity of CRON (4.64%) is better than 84.85% of its industry peers.
Industry RankSector Rank
ROA 4.29%
ROE 4.64%
ROIC N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
CRON Yearly ROA, ROE, ROICCRON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

1.3 Margins

CRON has a better Profit Margin (39.68%) than 97.47% of its industry peers.
CRON's Profit Margin has declined in the last couple of years.
The Gross Margin of CRON (27.65%) is comparable to the rest of the industry.
Industry RankSector Rank
OM N/A
PM (TTM) 39.68%
GM 27.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
CRON Yearly Profit, Operating, Gross MarginsCRON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

More info and screens

8

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CRON has more shares outstanding
Compared to 5 years ago, CRON has more shares outstanding
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRON Yearly Shares OutstandingCRON Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CRON Yearly Total Debt VS Total AssetsCRON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 6.87 indicates that CRON is not in any danger for bankruptcy at the moment.
CRON has a Altman-Z score of 6.87. This is amongst the best in the industry. CRON outperforms 85.86% of its industry peers.
CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.87
ROIC/WACCN/A
WACC8.49%
CRON Yearly LT Debt VS Equity VS FCFCRON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

CRON has a Current Ratio of 27.80. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
CRON has a better Current ratio (27.80) than 97.47% of its industry peers.
CRON has a Quick Ratio of 26.75. This indicates that CRON is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 26.75, CRON belongs to the best of the industry, outperforming 96.97% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 27.8
Quick Ratio 26.75
CRON Yearly Current Assets VS Current LiabilitesCRON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 285.71% over the past year.
The earnings per share for CRON have been decreasing by -50.78% on average. This is quite bad
Looking at the last year, CRON shows a very strong growth in Revenue. The Revenue has grown by 33.92%.
The Revenue has been growing by 37.71% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
Revenue 1Y (TTM)33.92%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%27.57%

3.2 Future

The Earnings Per Share is expected to decrease by -21.14% on average over the next years. This is quite bad
CRON is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.87% yearly.
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRON Yearly Revenue VS EstimatesCRON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M
CRON Yearly EPS VS EstimatesCRON Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 15.62 indicates a correct valuation of CRON.
Based on the Price/Earnings ratio, CRON is valued cheaper than 85.35% of the companies in the same industry.
CRON's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.82.
Based on the Price/Forward Earnings ratio of 24.88, the valuation of CRON can be described as rather expensive.
Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 73.74% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, CRON is valued at the same level.
Industry RankSector Rank
PE 15.62
Fwd PE 24.88
CRON Price Earnings VS Forward Price EarningsCRON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRON Per share dataCRON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

CRON's earnings are expected to decrease with -39.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%

More info and screens

0

5. Dividend

5.1 Amount

CRON does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRONOS GROUP INC

NASDAQ:CRON (5/23/2025, 9:24:33 PM)

After market: 2.0202 -0.01 (-0.48%)

2.03

-0.02 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners13.13%
Inst Owner Change1.35%
Ins Owners5.48%
Ins Owner Change12.71%
Market Cap782.38M
Analysts76
Price Target2.67 (31.53%)
Short Float %2.08%
Short Ratio2.55
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-7.6%
Min Revenue beat(2)-14.99%
Max Revenue beat(2)-0.21%
Revenue beat(4)2
Avg Revenue beat(4)-0.3%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)9.73%
Revenue beat(8)4
Avg Revenue beat(8)0.24%
Revenue beat(12)4
Avg Revenue beat(12)-4.65%
Revenue beat(16)7
Avg Revenue beat(16)-2.62%
PT rev (1m)4.26%
PT rev (3m)4.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-749.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.72%
Revenue NY rev (1m)2.63%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 15.62
Fwd PE 24.88
P/S 6.28
P/FCF N/A
P/OCF 41.28
P/B 0.73
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)0.13
EY6.4%
EPS(NY)0.08
Fwd EY4.02%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.05
OCFY2.42%
SpS0.32
BVpS2.77
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.29%
ROE 4.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 39.68%
GM 27.65%
FCFM N/A
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 253.86%
Cap/Sales 21.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.8
Quick Ratio 26.75
Altman-Z 6.87
F-Score6
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.71%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%300%
EPS Next Y-144.2%
EPS Next 2Y-9.67%
EPS Next 3Y-39.52%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)33.92%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%27.57%
Revenue Next Year18.44%
Revenue Next 2Y12.81%
Revenue Next 3Y7.09%
Revenue Next 5Y1.87%
EBIT growth 1Y32.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year90.36%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y92.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.45%
OCF growth 3YN/A
OCF growth 5YN/A